282 related articles for article (PubMed ID: 31054911)
1. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.
Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN
J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911
[TBL] [Abstract][Full Text] [Related]
2. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
[TBL] [Abstract][Full Text] [Related]
3. Mutation Status of
Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
[TBL] [Abstract][Full Text] [Related]
5. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
[TBL] [Abstract][Full Text] [Related]
6. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases.
Nishioka Y; Chun YS; Overman MJ; Cao HST; Tzeng CD; Mason MC; Kopetz SW; Bauer TW; Vauthey JN; Newhook TE;
J Am Coll Surg; 2022 Apr; 234(4):474-483. PubMed ID: 35290266
[TBL] [Abstract][Full Text] [Related]
7. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.
Brudvik KW; Mise Y; Chung MH; Chun YS; Kopetz SE; Passot G; Conrad C; Maru DM; Aloia TA; Vauthey JN
Ann Surg Oncol; 2016 Aug; 23(8):2635-43. PubMed ID: 27016292
[TBL] [Abstract][Full Text] [Related]
8. RAS/TP53 Co-mutation is Associated With Worse Survival After Concurrent Resection of Colorectal Liver Metastases and Extrahepatic Disease.
Lillemoe HA; Passot G; Kawaguchi Y; DeBellis M; Glehen O; Chun YS; Tzeng CD; Aloia TA; Lopez J; Vauthey JN
Ann Surg; 2022 Aug; 276(2):357-362. PubMed ID: 33351476
[TBL] [Abstract][Full Text] [Related]
9. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
Chun YS; Passot G; Yamashita S; Nusrat M; Katsonis P; Loree JM; Conrad C; Tzeng CD; Xiao L; Aloia TA; Eng C; Kopetz SE; Lichtarge O; Vauthey JN
Ann Surg; 2019 May; 269(5):917-923. PubMed ID: 28767562
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.
Kemeny NE; Chou JF; Capanu M; Gewirtz AN; Cercek A; Kingham TP; Jarnagin WR; Fong YC; DeMatteo RP; Allen PJ; Shia J; Ang C; Vakiani E; D'Angelica MI
Cancer; 2014 Dec; 120(24):3965-71. PubMed ID: 25155157
[TBL] [Abstract][Full Text] [Related]
11. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.
Zimmitti G; Shindoh J; Mise Y; Kopetz S; Loyer EM; Andreou A; Cooper AB; Kaur H; Aloia TA; Maru DM; Vauthey JN
Ann Surg Oncol; 2015 Mar; 22(3):834-842. PubMed ID: 25227306
[TBL] [Abstract][Full Text] [Related]
12. Colorectal Liver Micrometastases: Association with RAS/TP53 Co-Mutation and Prognosis after Surgery.
Chun YS; Passot G; Nishioka Y; Katkhuda R; Arvide EM; Benzerdjeb N; Lopez J; Kopetz SE; Maru DM; Vauthey JN
J Am Coll Surg; 2022 Jul; 235(1):8-16. PubMed ID: 35703957
[TBL] [Abstract][Full Text] [Related]
13. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C
Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130
[TBL] [Abstract][Full Text] [Related]
14. RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases.
Brudvik KW; Jones RP; Giuliante F; Shindoh J; Passot G; Chung MH; Song J; Li L; Dagenborg VJ; Fretland ÅA; Røsok B; De Rose AM; Ardito F; Edwin B; Panettieri E; Larocca LM; Yamashita S; Conrad C; Aloia TA; Poston GJ; Bjørnbeth BA; Vauthey JN
Ann Surg; 2019 Jan; 269(1):120-126. PubMed ID: 28549012
[TBL] [Abstract][Full Text] [Related]
15. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
17. Neither Surgical Margin Status nor Somatic Mutation Predicts Local Recurrence After R0-intent Resection for Colorectal Liver Metastases.
Nishioka Y; Paez-Arango N; Boettcher FO; Kawaguchi Y; Newhook TE; Chun YS; Tzeng CD; Tran Cao HS; Lee JE; Vreeland TJ; Vauthey JN
J Gastrointest Surg; 2022 Apr; 26(4):791-801. PubMed ID: 34725784
[TBL] [Abstract][Full Text] [Related]
18. A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status.
Kawaguchi Y; Kopetz S; Lillemoe HA; Hwang H; Wang X; Tzeng CD; Chun YS; Aloia TA; Vauthey JN
J Natl Compr Canc Netw; 2020 Nov; 18(11):1500-1508. PubMed ID: 33152698
[TBL] [Abstract][Full Text] [Related]
19. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
20. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]